Pacer Advisors’s ADMA Biologics ADMA Stock Holding History

Pacer Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$122K	Buy	+14,528	New	+$132K	﹤0.01%	1873
2025 Q4	–	Sell	-9,645	Closed	-$141K	–	3808
2025 Q3	$141K	Sell	9,645 -3	-0%	-$51	﹤0.01%	2093
2025 Q2	$176K	Buy	9,648 +2,016	+26%	+$41.1K	﹤0.01%	1888
2025 Q1	$151K	Sell	7,632 -30,598	-80%	-$529K	﹤0.01%	1861
2024 Q4	$656K	Sell	38,230 -866	-2%	-$16.3K	﹤0.01%	1517
2024 Q3	$782K	Buy	39,096 +37,504	+2,356%	+$583K	﹤0.01%	1487
2024 Q2	$17.8K	Sell	1,592 -1,582	-50%	-$13.3K	﹤0.01%	3451
2024 Q1	$20.9K	Buy	+3,174	New	+$17.3K	﹤0.01%	3436

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Pacer Advisors's ADMA Position: Q2 2026 in Review

Pacer Advisors opened a new position in ADMA Biologics (ADMA) in Q2 2026: 14,528 shares worth $122K. The stake represents ﹤0.01% of the portfolio and ranks #1873 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in ADMA as recently as Q3 2025.

Pacer Advisors first reported a position in ADMA in Q1 2024 and has held it in 8 quarters since. The position peaked at $782K in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Pacer Advisors held 14,528 shares of ADMA Biologics worth $122K as of Q2 2026.
ADMA Biologics was a new Pacer Advisors position in Q2 2026.
ADMA Biologics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #1873 holding.
Pacer Advisors first reported a position in ADMA Biologics in Q1 2024 and has held it in 8 quarters since.
Pacer Advisors's ADMA Biologics position peaked at $782K in Q3 2024.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.